Advertisement

Topics

ReNeuron Company Profile

16:39 EDT 23rd September 2018 | BioPortfolio

ReNeuron stem cell transplantation biotechnology for brain cell therapeutics to promote recovery of function.

Location

Europoint Centre , 5-11 Lavington Street
London
SE1 ONZ
United Kingdom

Contact

Phone: 0207 928 1720
Fax: 0207 261 0268
Email: renmail@reneuron.com


News Articles [21 Associated News Articles listed on BioPortfolio]

ReNeuron Group (RENE) - The rise of the exosome

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron introduced its exosome nanomedicine programme at its recent capital markets day. While being a preclinical programme...

ReNeuron Group (RENE) - US exclusivity deal - more than non-dilutive cash

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron ended FY18 with a healthy cash balance and the 11 July announcement of an exclusivity agreement worth up to US$5m wi...

ReNeuron Group (RENE) - Exosomes rise further

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron’s capital markets day highlighted the potential for the company’s exosome nanomedicine platform to be a ...

BRIEF—ReNeuron appoints new chief medical officer

UK cell-based therapies company ReNeuron today announced that Dr Richard Beckman has joined the company…

ReNeuron to resume discussions with other potential suitors as US pharma group backs out

The unnamed group’s decision not to progress to a definitive licensing agreement had nothing to do with ReNeuron’s technology, the company said

ReNeuron pens deal with undisclosed spec pharmaco

ReNeuron Group PLC licensed an undisclosed US specialty pharmaco exclusive global rights (excluding China) to its human retinal progenitor cells (hRPC) technology and therapeutic programs.

ReNeuron's Michael Hunt updates on product development

Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) chats to Proactive to update on the cell-based therapeutics specialist's research and development programmes. Hunt says they're to increase the n...

ReNeuron increases number of clinical sites in its PISCES III study

ReNeuron said it had taken the decision to increase the number of sites to ensure that patient recruitment targets in the study are met.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

ReNeuron

ReNeuron stem cell transplantation biotechnology for brain cell therapeutics to promote recovery of function.

ReNeuron Group plc

ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. We are also leveraging our ste...

More Information about "ReNeuron" on BioPortfolio

We have published hundreds of ReNeuron news stories on BioPortfolio along with dozens of ReNeuron Clinical Trials and PubMed Articles about ReNeuron for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ReNeuron Companies in our database. You can also find out about relevant ReNeuron Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record